A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

• Status: Recruiting
• Trial end date: 2029-01-16
• Target enrollment: 0
• Participant gender: Male

Summary

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer.

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Bristol-Myers Squibb

Criteria

Inclusion Criteria:

• Participant must have histologically or cytologically confirmed adenocarcinoma of the prostate.

• Participant must have an Eastern Cooperative Oncology Group (ECOG) performance status 0 to 1.

• Participant must have prostate specific antigen (PSA) of ≥ 2 ng/mL at Screening

• Participant must have progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)

Exclusion Criteria:

• Participant must not have history of brain metastases.

• Participant must not have impaired cardiac function or clinically significant cardiac disease.

• Participant must not have any significant medical condition, including active or uncontrolled infection, psychiatric illness, or the presence of laboratory abnormalities, which places the participant at unacceptable risk or prevent participation in the study based on Investigator assessment.

Other protocol-defined inclusion/exclusion criteria apply